NEUROLOGICAL SCIENCES-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2127748, encodeId=21ef212e74854, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：2022年7月29日投稿迟迟不外审，过了十月一国庆催了一下稿，外国人不过国庆哈，哈哈哈应该早点催稿 10月28日要求大修 11月17日返稿回去 12月11日接收了 12月20日Proof 12月22日available online 2023年4月正式见刊算是第一篇Sci，感觉还是很顺利的，审稿人的意见很中肯，确实提高了我的稿件质量，投稿体验还不错，如果卡住长时间不动可以发邮件催一下。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230422/fe9c91a3b5ed42adab1bad7bf9101bc7/db18785a63534e8ebf4f6b570394626e.jpg, createdBy=cc6e5681610, createdName=Leonliuy, createdTime=Sat Apr 22 22:29:11 CST 2023, time=2023-04-22, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=1233973, encodeId=9b7012339e316, content=审稿速度:2.0 经验分享：2022.6.2 New submission 2022.6.25 major revisions 2022.7.21 accept 比想象中快，不过这个是投到别的杂志再转投到Neurological Sciences的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=193d5506076, createdName=ms8000001755363788, createdTime=Fri Jul 22 09:33:15 CST 2022, time=2022-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2155735, encodeId=77092155e353b, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：外审回来，审稿人意见都很友好，但是被拒稿了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=32a18153103, createdName=ms9000001040526724, createdTime=Sat Sep 02 10:20:39 CST 2023, time=2023-09-02, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2154020, encodeId=d0ae215402035, content=审稿速度:6.0 | 投稿命中率:25.0 经验分享：无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0c1f3113130, createdName=weina_198062, createdTime=Tue Aug 22 10:32:17 CST 2023, time=2023-08-22, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2110224, encodeId=edb1211022464, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：血管介入方向； 2022-12-15左右投稿； 2023-1-10 小修 2023-1-12 接受 效率可；不过是转投的，至少值得转投吧！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/01/16/e92e0d4a11f64c95514f68e46da6590a.jpg, createdBy=51fb2303021, createdName=errormore, createdTime=Sat Jan 14 20:20:26 CST 2023, time=2023-01-14, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2106655, encodeId=2f012106655f9, content=请问有人知道论文已经Online ahead of print，但是版面费还没交，一般什么时候交版面费啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72f95640939, createdName=ms8000002097345763, createdTime=Mon Dec 19 12:57:14 CST 2022, time=2022-12-19, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2099702, encodeId=df742099e0282, content=审稿速度:2.0 | 投稿命中率:95.0 偏重的研究方向：自身免疫性脑炎;副肿瘤 经验分享：希望审稿周期短一点的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfc76416537, createdName=ms6000000132811253, createdTime=Thu Nov 10 17:49:07 CST 2022, time=2022-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1237916, encodeId=e3d5123e9161a, content=几个第一几个通讯, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dde62288731, createdName=121dfe5cm15暂无昵称, createdTime=Wed Aug 10 20:41:51 CST 2022, time=2022-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226684, encodeId=6e551226684eb, content=投稿命中率:50.0 经验分享：非常慢，甚至应该较很坑的杂志，分享一下自己的投稿撤稿历程：2021.9.25New submission；2021.10.9Editor Assigned；2021.11.4Under Review；2022.1.10Reviewers Invited；2022.1.13Under Review；2022.1.19Reviewers Invited；2022.1.22Under Review；2022.1.29Reviews completed；2022.1.31Editors decision；2022.2.3Major revision；2022.2.9Revision submitted；2022.2.11Editor Assigned；2022.2.15Reviewers Invited；2022.2.19 Under review；2022.2.27Reviewers Invited；2022.3.6Under review；2022.3.10Reviews completed；2022.3.24Reviewers Invited；2022.4.23Reviewers Invited；2022.4.23Under review；2022.5.7withdraw lettter；仍然under review；2022.5.22Reviewers Invited；2022.6.4撤稿成功。总共历时8个月，最终无奈撤稿，期间给编辑发邮件永远收不到回复。当然也能见到少数文章很快被接收，毕竟是少数，所以我的分享也只供大家参考，希望大家投稿顺利。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=450e5455452, createdName=ms4000001879393651, createdTime=Wed Jun 15 22:27:17 CST 2022, time=2022-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=892577, encodeId=b6978925e7ec, content=44天都没有送审，申请撤回了，大家别投了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=158, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ae035128370, createdName=1464e744m37暂无昵称, createdTime=Sat Oct 17 01:02:35 CST 2020, time=2020-10-17, status=1, ipAttribution=)]

2023-04-22 Leonliuy 来自天津

审稿速度:3.0 | 投稿命中率:50.0
经验分享：2022年7月29日投稿迟迟不外审，过了十月一国庆催了一下稿，外国人不过国庆哈，哈哈哈应该早点催稿 10月28日要求大修 11月17日返稿回去 12月11日接收了 12月20日Proof 12月22日available online 2023年4月正式见刊算是第一篇Sci，感觉还是很顺利的，审稿人的意见很中肯，确实提高了我的稿件质量，投稿体验还不错，如果卡住长时间不动可以发邮件催一下。

32 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2127748, encodeId=21ef212e74854, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：2022年7月29日投稿迟迟不外审，过了十月一国庆催了一下稿，外国人不过国庆哈，哈哈哈应该早点催稿 10月28日要求大修 11月17日返稿回去 12月11日接收了 12月20日Proof 12月22日available online 2023年4月正式见刊算是第一篇Sci，感觉还是很顺利的，审稿人的意见很中肯，确实提高了我的稿件质量，投稿体验还不错，如果卡住长时间不动可以发邮件催一下。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230422/fe9c91a3b5ed42adab1bad7bf9101bc7/db18785a63534e8ebf4f6b570394626e.jpg, createdBy=cc6e5681610, createdName=Leonliuy, createdTime=Sat Apr 22 22:29:11 CST 2023, time=2023-04-22, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=1233973, encodeId=9b7012339e316, content=审稿速度:2.0 经验分享：2022.6.2 New submission 2022.6.25 major revisions 2022.7.21 accept 比想象中快，不过这个是投到别的杂志再转投到Neurological Sciences的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=193d5506076, createdName=ms8000001755363788, createdTime=Fri Jul 22 09:33:15 CST 2022, time=2022-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2155735, encodeId=77092155e353b, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：外审回来，审稿人意见都很友好，但是被拒稿了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=32a18153103, createdName=ms9000001040526724, createdTime=Sat Sep 02 10:20:39 CST 2023, time=2023-09-02, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2154020, encodeId=d0ae215402035, content=审稿速度:6.0 | 投稿命中率:25.0 经验分享：无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0c1f3113130, createdName=weina_198062, createdTime=Tue Aug 22 10:32:17 CST 2023, time=2023-08-22, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2110224, encodeId=edb1211022464, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：血管介入方向； 2022-12-15左右投稿； 2023-1-10 小修 2023-1-12 接受 效率可；不过是转投的，至少值得转投吧！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/01/16/e92e0d4a11f64c95514f68e46da6590a.jpg, createdBy=51fb2303021, createdName=errormore, createdTime=Sat Jan 14 20:20:26 CST 2023, time=2023-01-14, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2106655, encodeId=2f012106655f9, content=请问有人知道论文已经Online ahead of print，但是版面费还没交，一般什么时候交版面费啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72f95640939, createdName=ms8000002097345763, createdTime=Mon Dec 19 12:57:14 CST 2022, time=2022-12-19, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2099702, encodeId=df742099e0282, content=审稿速度:2.0 | 投稿命中率:95.0 偏重的研究方向：自身免疫性脑炎;副肿瘤 经验分享：希望审稿周期短一点的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfc76416537, createdName=ms6000000132811253, createdTime=Thu Nov 10 17:49:07 CST 2022, time=2022-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1237916, encodeId=e3d5123e9161a, content=几个第一几个通讯, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dde62288731, createdName=121dfe5cm15暂无昵称, createdTime=Wed Aug 10 20:41:51 CST 2022, time=2022-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226684, encodeId=6e551226684eb, content=投稿命中率:50.0 经验分享：非常慢，甚至应该较很坑的杂志，分享一下自己的投稿撤稿历程：2021.9.25New submission；2021.10.9Editor Assigned；2021.11.4Under Review；2022.1.10Reviewers Invited；2022.1.13Under Review；2022.1.19Reviewers Invited；2022.1.22Under Review；2022.1.29Reviews completed；2022.1.31Editors decision；2022.2.3Major revision；2022.2.9Revision submitted；2022.2.11Editor Assigned；2022.2.15Reviewers Invited；2022.2.19 Under review；2022.2.27Reviewers Invited；2022.3.6Under review；2022.3.10Reviews completed；2022.3.24Reviewers Invited；2022.4.23Reviewers Invited；2022.4.23Under review；2022.5.7withdraw lettter；仍然under review；2022.5.22Reviewers Invited；2022.6.4撤稿成功。总共历时8个月，最终无奈撤稿，期间给编辑发邮件永远收不到回复。当然也能见到少数文章很快被接收，毕竟是少数，所以我的分享也只供大家参考，希望大家投稿顺利。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=450e5455452, createdName=ms4000001879393651, createdTime=Wed Jun 15 22:27:17 CST 2022, time=2022-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=892577, encodeId=b6978925e7ec, content=44天都没有送审，申请撤回了，大家别投了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=158, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ae035128370, createdName=1464e744m37暂无昵称, createdTime=Sat Oct 17 01:02:35 CST 2020, time=2020-10-17, status=1, ipAttribution=)]

2022-07-22 ms8000001755363788

审稿速度:2.0
经验分享：2022.6.2 New submission 2022.6.25 major revisions 2022.7.21 accept 比想象中快，不过这个是投到别的杂志再转投到Neurological Sciences的。

53 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2127748, encodeId=21ef212e74854, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：2022年7月29日投稿迟迟不外审，过了十月一国庆催了一下稿，外国人不过国庆哈，哈哈哈应该早点催稿 10月28日要求大修 11月17日返稿回去 12月11日接收了 12月20日Proof 12月22日available online 2023年4月正式见刊算是第一篇Sci，感觉还是很顺利的，审稿人的意见很中肯，确实提高了我的稿件质量，投稿体验还不错，如果卡住长时间不动可以发邮件催一下。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230422/fe9c91a3b5ed42adab1bad7bf9101bc7/db18785a63534e8ebf4f6b570394626e.jpg, createdBy=cc6e5681610, createdName=Leonliuy, createdTime=Sat Apr 22 22:29:11 CST 2023, time=2023-04-22, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=1233973, encodeId=9b7012339e316, content=审稿速度:2.0 经验分享：2022.6.2 New submission 2022.6.25 major revisions 2022.7.21 accept 比想象中快，不过这个是投到别的杂志再转投到Neurological Sciences的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=193d5506076, createdName=ms8000001755363788, createdTime=Fri Jul 22 09:33:15 CST 2022, time=2022-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2155735, encodeId=77092155e353b, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：外审回来，审稿人意见都很友好，但是被拒稿了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=32a18153103, createdName=ms9000001040526724, createdTime=Sat Sep 02 10:20:39 CST 2023, time=2023-09-02, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2154020, encodeId=d0ae215402035, content=审稿速度:6.0 | 投稿命中率:25.0 经验分享：无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0c1f3113130, createdName=weina_198062, createdTime=Tue Aug 22 10:32:17 CST 2023, time=2023-08-22, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2110224, encodeId=edb1211022464, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：血管介入方向； 2022-12-15左右投稿； 2023-1-10 小修 2023-1-12 接受 效率可；不过是转投的，至少值得转投吧！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/01/16/e92e0d4a11f64c95514f68e46da6590a.jpg, createdBy=51fb2303021, createdName=errormore, createdTime=Sat Jan 14 20:20:26 CST 2023, time=2023-01-14, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2106655, encodeId=2f012106655f9, content=请问有人知道论文已经Online ahead of print，但是版面费还没交，一般什么时候交版面费啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72f95640939, createdName=ms8000002097345763, createdTime=Mon Dec 19 12:57:14 CST 2022, time=2022-12-19, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2099702, encodeId=df742099e0282, content=审稿速度:2.0 | 投稿命中率:95.0 偏重的研究方向：自身免疫性脑炎;副肿瘤 经验分享：希望审稿周期短一点的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfc76416537, createdName=ms6000000132811253, createdTime=Thu Nov 10 17:49:07 CST 2022, time=2022-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1237916, encodeId=e3d5123e9161a, content=几个第一几个通讯, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dde62288731, createdName=121dfe5cm15暂无昵称, createdTime=Wed Aug 10 20:41:51 CST 2022, time=2022-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226684, encodeId=6e551226684eb, content=投稿命中率:50.0 经验分享：非常慢，甚至应该较很坑的杂志，分享一下自己的投稿撤稿历程：2021.9.25New submission；2021.10.9Editor Assigned；2021.11.4Under Review；2022.1.10Reviewers Invited；2022.1.13Under Review；2022.1.19Reviewers Invited；2022.1.22Under Review；2022.1.29Reviews completed；2022.1.31Editors decision；2022.2.3Major revision；2022.2.9Revision submitted；2022.2.11Editor Assigned；2022.2.15Reviewers Invited；2022.2.19 Under review；2022.2.27Reviewers Invited；2022.3.6Under review；2022.3.10Reviews completed；2022.3.24Reviewers Invited；2022.4.23Reviewers Invited；2022.4.23Under review；2022.5.7withdraw lettter；仍然under review；2022.5.22Reviewers Invited；2022.6.4撤稿成功。总共历时8个月，最终无奈撤稿，期间给编辑发邮件永远收不到回复。当然也能见到少数文章很快被接收，毕竟是少数，所以我的分享也只供大家参考，希望大家投稿顺利。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=450e5455452, createdName=ms4000001879393651, createdTime=Wed Jun 15 22:27:17 CST 2022, time=2022-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=892577, encodeId=b6978925e7ec, content=44天都没有送审，申请撤回了，大家别投了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=158, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ae035128370, createdName=1464e744m37暂无昵称, createdTime=Sat Oct 17 01:02:35 CST 2020, time=2020-10-17, status=1, ipAttribution=)]

2023-09-02 ms9000001040526724 来自四川省

审稿速度:3.0 | 投稿命中率:50.0
经验分享：外审回来，审稿人意见都很友好，但是被拒稿了

25 0

[GetPortalCommentsPageByObjectIdResponse(id=2127748, encodeId=21ef212e74854, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：2022年7月29日投稿迟迟不外审，过了十月一国庆催了一下稿，外国人不过国庆哈，哈哈哈应该早点催稿 10月28日要求大修 11月17日返稿回去 12月11日接收了 12月20日Proof 12月22日available online 2023年4月正式见刊算是第一篇Sci，感觉还是很顺利的，审稿人的意见很中肯，确实提高了我的稿件质量，投稿体验还不错，如果卡住长时间不动可以发邮件催一下。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230422/fe9c91a3b5ed42adab1bad7bf9101bc7/db18785a63534e8ebf4f6b570394626e.jpg, createdBy=cc6e5681610, createdName=Leonliuy, createdTime=Sat Apr 22 22:29:11 CST 2023, time=2023-04-22, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=1233973, encodeId=9b7012339e316, content=审稿速度:2.0 经验分享：2022.6.2 New submission 2022.6.25 major revisions 2022.7.21 accept 比想象中快，不过这个是投到别的杂志再转投到Neurological Sciences的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=193d5506076, createdName=ms8000001755363788, createdTime=Fri Jul 22 09:33:15 CST 2022, time=2022-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2155735, encodeId=77092155e353b, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：外审回来，审稿人意见都很友好，但是被拒稿了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=32a18153103, createdName=ms9000001040526724, createdTime=Sat Sep 02 10:20:39 CST 2023, time=2023-09-02, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2154020, encodeId=d0ae215402035, content=审稿速度:6.0 | 投稿命中率:25.0 经验分享：无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0c1f3113130, createdName=weina_198062, createdTime=Tue Aug 22 10:32:17 CST 2023, time=2023-08-22, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2110224, encodeId=edb1211022464, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：血管介入方向； 2022-12-15左右投稿； 2023-1-10 小修 2023-1-12 接受 效率可；不过是转投的，至少值得转投吧！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/01/16/e92e0d4a11f64c95514f68e46da6590a.jpg, createdBy=51fb2303021, createdName=errormore, createdTime=Sat Jan 14 20:20:26 CST 2023, time=2023-01-14, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2106655, encodeId=2f012106655f9, content=请问有人知道论文已经Online ahead of print，但是版面费还没交，一般什么时候交版面费啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72f95640939, createdName=ms8000002097345763, createdTime=Mon Dec 19 12:57:14 CST 2022, time=2022-12-19, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2099702, encodeId=df742099e0282, content=审稿速度:2.0 | 投稿命中率:95.0 偏重的研究方向：自身免疫性脑炎;副肿瘤 经验分享：希望审稿周期短一点的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfc76416537, createdName=ms6000000132811253, createdTime=Thu Nov 10 17:49:07 CST 2022, time=2022-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1237916, encodeId=e3d5123e9161a, content=几个第一几个通讯, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dde62288731, createdName=121dfe5cm15暂无昵称, createdTime=Wed Aug 10 20:41:51 CST 2022, time=2022-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226684, encodeId=6e551226684eb, content=投稿命中率:50.0 经验分享：非常慢，甚至应该较很坑的杂志，分享一下自己的投稿撤稿历程：2021.9.25New submission；2021.10.9Editor Assigned；2021.11.4Under Review；2022.1.10Reviewers Invited；2022.1.13Under Review；2022.1.19Reviewers Invited；2022.1.22Under Review；2022.1.29Reviews completed；2022.1.31Editors decision；2022.2.3Major revision；2022.2.9Revision submitted；2022.2.11Editor Assigned；2022.2.15Reviewers Invited；2022.2.19 Under review；2022.2.27Reviewers Invited；2022.3.6Under review；2022.3.10Reviews completed；2022.3.24Reviewers Invited；2022.4.23Reviewers Invited；2022.4.23Under review；2022.5.7withdraw lettter；仍然under review；2022.5.22Reviewers Invited；2022.6.4撤稿成功。总共历时8个月，最终无奈撤稿，期间给编辑发邮件永远收不到回复。当然也能见到少数文章很快被接收，毕竟是少数，所以我的分享也只供大家参考，希望大家投稿顺利。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=450e5455452, createdName=ms4000001879393651, createdTime=Wed Jun 15 22:27:17 CST 2022, time=2022-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=892577, encodeId=b6978925e7ec, content=44天都没有送审，申请撤回了，大家别投了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=158, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ae035128370, createdName=1464e744m37暂无昵称, createdTime=Sat Oct 17 01:02:35 CST 2020, time=2020-10-17, status=1, ipAttribution=)]

2023-08-22 weina_198062 来自北京

审稿速度:6.0 | 投稿命中率:25.0
经验分享：无

29 0

[GetPortalCommentsPageByObjectIdResponse(id=2127748, encodeId=21ef212e74854, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：2022年7月29日投稿迟迟不外审，过了十月一国庆催了一下稿，外国人不过国庆哈，哈哈哈应该早点催稿 10月28日要求大修 11月17日返稿回去 12月11日接收了 12月20日Proof 12月22日available online 2023年4月正式见刊算是第一篇Sci，感觉还是很顺利的，审稿人的意见很中肯，确实提高了我的稿件质量，投稿体验还不错，如果卡住长时间不动可以发邮件催一下。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230422/fe9c91a3b5ed42adab1bad7bf9101bc7/db18785a63534e8ebf4f6b570394626e.jpg, createdBy=cc6e5681610, createdName=Leonliuy, createdTime=Sat Apr 22 22:29:11 CST 2023, time=2023-04-22, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=1233973, encodeId=9b7012339e316, content=审稿速度:2.0 经验分享：2022.6.2 New submission 2022.6.25 major revisions 2022.7.21 accept 比想象中快，不过这个是投到别的杂志再转投到Neurological Sciences的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=193d5506076, createdName=ms8000001755363788, createdTime=Fri Jul 22 09:33:15 CST 2022, time=2022-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2155735, encodeId=77092155e353b, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：外审回来，审稿人意见都很友好，但是被拒稿了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=32a18153103, createdName=ms9000001040526724, createdTime=Sat Sep 02 10:20:39 CST 2023, time=2023-09-02, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2154020, encodeId=d0ae215402035, content=审稿速度:6.0 | 投稿命中率:25.0 经验分享：无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0c1f3113130, createdName=weina_198062, createdTime=Tue Aug 22 10:32:17 CST 2023, time=2023-08-22, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2110224, encodeId=edb1211022464, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：血管介入方向； 2022-12-15左右投稿； 2023-1-10 小修 2023-1-12 接受 效率可；不过是转投的，至少值得转投吧！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/01/16/e92e0d4a11f64c95514f68e46da6590a.jpg, createdBy=51fb2303021, createdName=errormore, createdTime=Sat Jan 14 20:20:26 CST 2023, time=2023-01-14, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2106655, encodeId=2f012106655f9, content=请问有人知道论文已经Online ahead of print，但是版面费还没交，一般什么时候交版面费啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72f95640939, createdName=ms8000002097345763, createdTime=Mon Dec 19 12:57:14 CST 2022, time=2022-12-19, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2099702, encodeId=df742099e0282, content=审稿速度:2.0 | 投稿命中率:95.0 偏重的研究方向：自身免疫性脑炎;副肿瘤 经验分享：希望审稿周期短一点的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfc76416537, createdName=ms6000000132811253, createdTime=Thu Nov 10 17:49:07 CST 2022, time=2022-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1237916, encodeId=e3d5123e9161a, content=几个第一几个通讯, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dde62288731, createdName=121dfe5cm15暂无昵称, createdTime=Wed Aug 10 20:41:51 CST 2022, time=2022-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226684, encodeId=6e551226684eb, content=投稿命中率:50.0 经验分享：非常慢，甚至应该较很坑的杂志，分享一下自己的投稿撤稿历程：2021.9.25New submission；2021.10.9Editor Assigned；2021.11.4Under Review；2022.1.10Reviewers Invited；2022.1.13Under Review；2022.1.19Reviewers Invited；2022.1.22Under Review；2022.1.29Reviews completed；2022.1.31Editors decision；2022.2.3Major revision；2022.2.9Revision submitted；2022.2.11Editor Assigned；2022.2.15Reviewers Invited；2022.2.19 Under review；2022.2.27Reviewers Invited；2022.3.6Under review；2022.3.10Reviews completed；2022.3.24Reviewers Invited；2022.4.23Reviewers Invited；2022.4.23Under review；2022.5.7withdraw lettter；仍然under review；2022.5.22Reviewers Invited；2022.6.4撤稿成功。总共历时8个月，最终无奈撤稿，期间给编辑发邮件永远收不到回复。当然也能见到少数文章很快被接收，毕竟是少数，所以我的分享也只供大家参考，希望大家投稿顺利。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=450e5455452, createdName=ms4000001879393651, createdTime=Wed Jun 15 22:27:17 CST 2022, time=2022-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=892577, encodeId=b6978925e7ec, content=44天都没有送审，申请撤回了，大家别投了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=158, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ae035128370, createdName=1464e744m37暂无昵称, createdTime=Sat Oct 17 01:02:35 CST 2020, time=2020-10-17, status=1, ipAttribution=)]

2023-01-14 errormore 来自江苏省

审稿速度:1.0 | 投稿命中率:75.0
经验分享：血管介入方向；
2022-12-15左右投稿；
2023-1-10 小修
2023-1-12 接受
效率可；不过是转投的，至少值得转投吧！

39 0

[GetPortalCommentsPageByObjectIdResponse(id=2127748, encodeId=21ef212e74854, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：2022年7月29日投稿迟迟不外审，过了十月一国庆催了一下稿，外国人不过国庆哈，哈哈哈应该早点催稿 10月28日要求大修 11月17日返稿回去 12月11日接收了 12月20日Proof 12月22日available online 2023年4月正式见刊算是第一篇Sci，感觉还是很顺利的，审稿人的意见很中肯，确实提高了我的稿件质量，投稿体验还不错，如果卡住长时间不动可以发邮件催一下。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230422/fe9c91a3b5ed42adab1bad7bf9101bc7/db18785a63534e8ebf4f6b570394626e.jpg, createdBy=cc6e5681610, createdName=Leonliuy, createdTime=Sat Apr 22 22:29:11 CST 2023, time=2023-04-22, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=1233973, encodeId=9b7012339e316, content=审稿速度:2.0 经验分享：2022.6.2 New submission 2022.6.25 major revisions 2022.7.21 accept 比想象中快，不过这个是投到别的杂志再转投到Neurological Sciences的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=193d5506076, createdName=ms8000001755363788, createdTime=Fri Jul 22 09:33:15 CST 2022, time=2022-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2155735, encodeId=77092155e353b, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：外审回来，审稿人意见都很友好，但是被拒稿了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=32a18153103, createdName=ms9000001040526724, createdTime=Sat Sep 02 10:20:39 CST 2023, time=2023-09-02, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2154020, encodeId=d0ae215402035, content=审稿速度:6.0 | 投稿命中率:25.0 经验分享：无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0c1f3113130, createdName=weina_198062, createdTime=Tue Aug 22 10:32:17 CST 2023, time=2023-08-22, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2110224, encodeId=edb1211022464, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：血管介入方向； 2022-12-15左右投稿； 2023-1-10 小修 2023-1-12 接受 效率可；不过是转投的，至少值得转投吧！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/01/16/e92e0d4a11f64c95514f68e46da6590a.jpg, createdBy=51fb2303021, createdName=errormore, createdTime=Sat Jan 14 20:20:26 CST 2023, time=2023-01-14, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2106655, encodeId=2f012106655f9, content=请问有人知道论文已经Online ahead of print，但是版面费还没交，一般什么时候交版面费啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72f95640939, createdName=ms8000002097345763, createdTime=Mon Dec 19 12:57:14 CST 2022, time=2022-12-19, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2099702, encodeId=df742099e0282, content=审稿速度:2.0 | 投稿命中率:95.0 偏重的研究方向：自身免疫性脑炎;副肿瘤 经验分享：希望审稿周期短一点的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfc76416537, createdName=ms6000000132811253, createdTime=Thu Nov 10 17:49:07 CST 2022, time=2022-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1237916, encodeId=e3d5123e9161a, content=几个第一几个通讯, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dde62288731, createdName=121dfe5cm15暂无昵称, createdTime=Wed Aug 10 20:41:51 CST 2022, time=2022-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226684, encodeId=6e551226684eb, content=投稿命中率:50.0 经验分享：非常慢，甚至应该较很坑的杂志，分享一下自己的投稿撤稿历程：2021.9.25New submission；2021.10.9Editor Assigned；2021.11.4Under Review；2022.1.10Reviewers Invited；2022.1.13Under Review；2022.1.19Reviewers Invited；2022.1.22Under Review；2022.1.29Reviews completed；2022.1.31Editors decision；2022.2.3Major revision；2022.2.9Revision submitted；2022.2.11Editor Assigned；2022.2.15Reviewers Invited；2022.2.19 Under review；2022.2.27Reviewers Invited；2022.3.6Under review；2022.3.10Reviews completed；2022.3.24Reviewers Invited；2022.4.23Reviewers Invited；2022.4.23Under review；2022.5.7withdraw lettter；仍然under review；2022.5.22Reviewers Invited；2022.6.4撤稿成功。总共历时8个月，最终无奈撤稿，期间给编辑发邮件永远收不到回复。当然也能见到少数文章很快被接收，毕竟是少数，所以我的分享也只供大家参考，希望大家投稿顺利。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=450e5455452, createdName=ms4000001879393651, createdTime=Wed Jun 15 22:27:17 CST 2022, time=2022-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=892577, encodeId=b6978925e7ec, content=44天都没有送审，申请撤回了，大家别投了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=158, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ae035128370, createdName=1464e744m37暂无昵称, createdTime=Sat Oct 17 01:02:35 CST 2020, time=2020-10-17, status=1, ipAttribution=)]

2022-12-19 ms8000002097345763 来自湖北省

请问有人知道论文已经Online ahead of print，但是版面费还没交，一般什么时候交版面费啊？

40 0

[GetPortalCommentsPageByObjectIdResponse(id=2127748, encodeId=21ef212e74854, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：2022年7月29日投稿迟迟不外审，过了十月一国庆催了一下稿，外国人不过国庆哈，哈哈哈应该早点催稿 10月28日要求大修 11月17日返稿回去 12月11日接收了 12月20日Proof 12月22日available online 2023年4月正式见刊算是第一篇Sci，感觉还是很顺利的，审稿人的意见很中肯，确实提高了我的稿件质量，投稿体验还不错，如果卡住长时间不动可以发邮件催一下。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230422/fe9c91a3b5ed42adab1bad7bf9101bc7/db18785a63534e8ebf4f6b570394626e.jpg, createdBy=cc6e5681610, createdName=Leonliuy, createdTime=Sat Apr 22 22:29:11 CST 2023, time=2023-04-22, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=1233973, encodeId=9b7012339e316, content=审稿速度:2.0 经验分享：2022.6.2 New submission 2022.6.25 major revisions 2022.7.21 accept 比想象中快，不过这个是投到别的杂志再转投到Neurological Sciences的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=193d5506076, createdName=ms8000001755363788, createdTime=Fri Jul 22 09:33:15 CST 2022, time=2022-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2155735, encodeId=77092155e353b, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：外审回来，审稿人意见都很友好，但是被拒稿了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=32a18153103, createdName=ms9000001040526724, createdTime=Sat Sep 02 10:20:39 CST 2023, time=2023-09-02, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2154020, encodeId=d0ae215402035, content=审稿速度:6.0 | 投稿命中率:25.0 经验分享：无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0c1f3113130, createdName=weina_198062, createdTime=Tue Aug 22 10:32:17 CST 2023, time=2023-08-22, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2110224, encodeId=edb1211022464, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：血管介入方向； 2022-12-15左右投稿； 2023-1-10 小修 2023-1-12 接受 效率可；不过是转投的，至少值得转投吧！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/01/16/e92e0d4a11f64c95514f68e46da6590a.jpg, createdBy=51fb2303021, createdName=errormore, createdTime=Sat Jan 14 20:20:26 CST 2023, time=2023-01-14, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2106655, encodeId=2f012106655f9, content=请问有人知道论文已经Online ahead of print，但是版面费还没交，一般什么时候交版面费啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72f95640939, createdName=ms8000002097345763, createdTime=Mon Dec 19 12:57:14 CST 2022, time=2022-12-19, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2099702, encodeId=df742099e0282, content=审稿速度:2.0 | 投稿命中率:95.0 偏重的研究方向：自身免疫性脑炎;副肿瘤 经验分享：希望审稿周期短一点的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfc76416537, createdName=ms6000000132811253, createdTime=Thu Nov 10 17:49:07 CST 2022, time=2022-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1237916, encodeId=e3d5123e9161a, content=几个第一几个通讯, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dde62288731, createdName=121dfe5cm15暂无昵称, createdTime=Wed Aug 10 20:41:51 CST 2022, time=2022-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226684, encodeId=6e551226684eb, content=投稿命中率:50.0 经验分享：非常慢，甚至应该较很坑的杂志，分享一下自己的投稿撤稿历程：2021.9.25New submission；2021.10.9Editor Assigned；2021.11.4Under Review；2022.1.10Reviewers Invited；2022.1.13Under Review；2022.1.19Reviewers Invited；2022.1.22Under Review；2022.1.29Reviews completed；2022.1.31Editors decision；2022.2.3Major revision；2022.2.9Revision submitted；2022.2.11Editor Assigned；2022.2.15Reviewers Invited；2022.2.19 Under review；2022.2.27Reviewers Invited；2022.3.6Under review；2022.3.10Reviews completed；2022.3.24Reviewers Invited；2022.4.23Reviewers Invited；2022.4.23Under review；2022.5.7withdraw lettter；仍然under review；2022.5.22Reviewers Invited；2022.6.4撤稿成功。总共历时8个月，最终无奈撤稿，期间给编辑发邮件永远收不到回复。当然也能见到少数文章很快被接收，毕竟是少数，所以我的分享也只供大家参考，希望大家投稿顺利。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=450e5455452, createdName=ms4000001879393651, createdTime=Wed Jun 15 22:27:17 CST 2022, time=2022-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=892577, encodeId=b6978925e7ec, content=44天都没有送审，申请撤回了，大家别投了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=158, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ae035128370, createdName=1464e744m37暂无昵称, createdTime=Sat Oct 17 01:02:35 CST 2020, time=2020-10-17, status=1, ipAttribution=)]

2022-11-10 ms6000000132811253

审稿速度:2.0 | 投稿命中率:95.0
偏重的研究方向：自身免疫性脑炎;副肿瘤
经验分享：希望审稿周期短一点的

45 0

[GetPortalCommentsPageByObjectIdResponse(id=2127748, encodeId=21ef212e74854, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：2022年7月29日投稿迟迟不外审，过了十月一国庆催了一下稿，外国人不过国庆哈，哈哈哈应该早点催稿 10月28日要求大修 11月17日返稿回去 12月11日接收了 12月20日Proof 12月22日available online 2023年4月正式见刊算是第一篇Sci，感觉还是很顺利的，审稿人的意见很中肯，确实提高了我的稿件质量，投稿体验还不错，如果卡住长时间不动可以发邮件催一下。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230422/fe9c91a3b5ed42adab1bad7bf9101bc7/db18785a63534e8ebf4f6b570394626e.jpg, createdBy=cc6e5681610, createdName=Leonliuy, createdTime=Sat Apr 22 22:29:11 CST 2023, time=2023-04-22, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=1233973, encodeId=9b7012339e316, content=审稿速度:2.0 经验分享：2022.6.2 New submission 2022.6.25 major revisions 2022.7.21 accept 比想象中快，不过这个是投到别的杂志再转投到Neurological Sciences的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=193d5506076, createdName=ms8000001755363788, createdTime=Fri Jul 22 09:33:15 CST 2022, time=2022-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2155735, encodeId=77092155e353b, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：外审回来，审稿人意见都很友好，但是被拒稿了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=32a18153103, createdName=ms9000001040526724, createdTime=Sat Sep 02 10:20:39 CST 2023, time=2023-09-02, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2154020, encodeId=d0ae215402035, content=审稿速度:6.0 | 投稿命中率:25.0 经验分享：无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0c1f3113130, createdName=weina_198062, createdTime=Tue Aug 22 10:32:17 CST 2023, time=2023-08-22, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2110224, encodeId=edb1211022464, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：血管介入方向； 2022-12-15左右投稿； 2023-1-10 小修 2023-1-12 接受 效率可；不过是转投的，至少值得转投吧！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/01/16/e92e0d4a11f64c95514f68e46da6590a.jpg, createdBy=51fb2303021, createdName=errormore, createdTime=Sat Jan 14 20:20:26 CST 2023, time=2023-01-14, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2106655, encodeId=2f012106655f9, content=请问有人知道论文已经Online ahead of print，但是版面费还没交，一般什么时候交版面费啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72f95640939, createdName=ms8000002097345763, createdTime=Mon Dec 19 12:57:14 CST 2022, time=2022-12-19, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2099702, encodeId=df742099e0282, content=审稿速度:2.0 | 投稿命中率:95.0 偏重的研究方向：自身免疫性脑炎;副肿瘤 经验分享：希望审稿周期短一点的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfc76416537, createdName=ms6000000132811253, createdTime=Thu Nov 10 17:49:07 CST 2022, time=2022-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1237916, encodeId=e3d5123e9161a, content=几个第一几个通讯, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dde62288731, createdName=121dfe5cm15暂无昵称, createdTime=Wed Aug 10 20:41:51 CST 2022, time=2022-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226684, encodeId=6e551226684eb, content=投稿命中率:50.0 经验分享：非常慢，甚至应该较很坑的杂志，分享一下自己的投稿撤稿历程：2021.9.25New submission；2021.10.9Editor Assigned；2021.11.4Under Review；2022.1.10Reviewers Invited；2022.1.13Under Review；2022.1.19Reviewers Invited；2022.1.22Under Review；2022.1.29Reviews completed；2022.1.31Editors decision；2022.2.3Major revision；2022.2.9Revision submitted；2022.2.11Editor Assigned；2022.2.15Reviewers Invited；2022.2.19 Under review；2022.2.27Reviewers Invited；2022.3.6Under review；2022.3.10Reviews completed；2022.3.24Reviewers Invited；2022.4.23Reviewers Invited；2022.4.23Under review；2022.5.7withdraw lettter；仍然under review；2022.5.22Reviewers Invited；2022.6.4撤稿成功。总共历时8个月，最终无奈撤稿，期间给编辑发邮件永远收不到回复。当然也能见到少数文章很快被接收，毕竟是少数，所以我的分享也只供大家参考，希望大家投稿顺利。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=450e5455452, createdName=ms4000001879393651, createdTime=Wed Jun 15 22:27:17 CST 2022, time=2022-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=892577, encodeId=b6978925e7ec, content=44天都没有送审，申请撤回了，大家别投了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=158, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ae035128370, createdName=1464e744m37暂无昵称, createdTime=Sat Oct 17 01:02:35 CST 2020, time=2020-10-17, status=1, ipAttribution=)]

2022-08-10 121dfe5cm15暂无昵称

几个第一几个通讯

39 0

[GetPortalCommentsPageByObjectIdResponse(id=2127748, encodeId=21ef212e74854, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：2022年7月29日投稿迟迟不外审，过了十月一国庆催了一下稿，外国人不过国庆哈，哈哈哈应该早点催稿 10月28日要求大修 11月17日返稿回去 12月11日接收了 12月20日Proof 12月22日available online 2023年4月正式见刊算是第一篇Sci，感觉还是很顺利的，审稿人的意见很中肯，确实提高了我的稿件质量，投稿体验还不错，如果卡住长时间不动可以发邮件催一下。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230422/fe9c91a3b5ed42adab1bad7bf9101bc7/db18785a63534e8ebf4f6b570394626e.jpg, createdBy=cc6e5681610, createdName=Leonliuy, createdTime=Sat Apr 22 22:29:11 CST 2023, time=2023-04-22, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=1233973, encodeId=9b7012339e316, content=审稿速度:2.0 经验分享：2022.6.2 New submission 2022.6.25 major revisions 2022.7.21 accept 比想象中快，不过这个是投到别的杂志再转投到Neurological Sciences的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=193d5506076, createdName=ms8000001755363788, createdTime=Fri Jul 22 09:33:15 CST 2022, time=2022-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2155735, encodeId=77092155e353b, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：外审回来，审稿人意见都很友好，但是被拒稿了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=32a18153103, createdName=ms9000001040526724, createdTime=Sat Sep 02 10:20:39 CST 2023, time=2023-09-02, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2154020, encodeId=d0ae215402035, content=审稿速度:6.0 | 投稿命中率:25.0 经验分享：无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0c1f3113130, createdName=weina_198062, createdTime=Tue Aug 22 10:32:17 CST 2023, time=2023-08-22, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2110224, encodeId=edb1211022464, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：血管介入方向； 2022-12-15左右投稿； 2023-1-10 小修 2023-1-12 接受 效率可；不过是转投的，至少值得转投吧！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/01/16/e92e0d4a11f64c95514f68e46da6590a.jpg, createdBy=51fb2303021, createdName=errormore, createdTime=Sat Jan 14 20:20:26 CST 2023, time=2023-01-14, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2106655, encodeId=2f012106655f9, content=请问有人知道论文已经Online ahead of print，但是版面费还没交，一般什么时候交版面费啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72f95640939, createdName=ms8000002097345763, createdTime=Mon Dec 19 12:57:14 CST 2022, time=2022-12-19, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2099702, encodeId=df742099e0282, content=审稿速度:2.0 | 投稿命中率:95.0 偏重的研究方向：自身免疫性脑炎;副肿瘤 经验分享：希望审稿周期短一点的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfc76416537, createdName=ms6000000132811253, createdTime=Thu Nov 10 17:49:07 CST 2022, time=2022-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1237916, encodeId=e3d5123e9161a, content=几个第一几个通讯, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dde62288731, createdName=121dfe5cm15暂无昵称, createdTime=Wed Aug 10 20:41:51 CST 2022, time=2022-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226684, encodeId=6e551226684eb, content=投稿命中率:50.0 经验分享：非常慢，甚至应该较很坑的杂志，分享一下自己的投稿撤稿历程：2021.9.25New submission；2021.10.9Editor Assigned；2021.11.4Under Review；2022.1.10Reviewers Invited；2022.1.13Under Review；2022.1.19Reviewers Invited；2022.1.22Under Review；2022.1.29Reviews completed；2022.1.31Editors decision；2022.2.3Major revision；2022.2.9Revision submitted；2022.2.11Editor Assigned；2022.2.15Reviewers Invited；2022.2.19 Under review；2022.2.27Reviewers Invited；2022.3.6Under review；2022.3.10Reviews completed；2022.3.24Reviewers Invited；2022.4.23Reviewers Invited；2022.4.23Under review；2022.5.7withdraw lettter；仍然under review；2022.5.22Reviewers Invited；2022.6.4撤稿成功。总共历时8个月，最终无奈撤稿，期间给编辑发邮件永远收不到回复。当然也能见到少数文章很快被接收，毕竟是少数，所以我的分享也只供大家参考，希望大家投稿顺利。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=450e5455452, createdName=ms4000001879393651, createdTime=Wed Jun 15 22:27:17 CST 2022, time=2022-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=892577, encodeId=b6978925e7ec, content=44天都没有送审，申请撤回了，大家别投了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=158, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ae035128370, createdName=1464e744m37暂无昵称, createdTime=Sat Oct 17 01:02:35 CST 2020, time=2020-10-17, status=1, ipAttribution=)]

2022-06-15 ms4000001879393651

投稿命中率:50.0
经验分享：非常慢，甚至应该较很坑的杂志，分享一下自己的投稿撤稿历程：2021.9.25New submission；2021.10.9Editor Assigned；2021.11.4Under Review；2022.1.10Reviewers Invited；2022.1.13Under Review；2022.1.19Reviewers Invited；2022.1.22Under Review；2022.1.29Reviews completed；2022.1.31Editors decision；2022.2.3Major revision；2022.2.9Revision submitted；2022.2.11Editor Assigned；2022.2.15Reviewers Invited；2022.2.19 Under review；2022.2.27Reviewers Invited；2022.3.6Under review；2022.3.10Reviews completed；2022.3.24Reviewers Invited；2022.4.23Reviewers Invited；2022.4.23Under review；2022.5.7withdraw lettter；仍然under review；2022.5.22Reviewers Invited；2022.6.4撤稿成功。总共历时8个月，最终无奈撤稿，期间给编辑发邮件永远收不到回复。当然也能见到少数文章很快被接收，毕竟是少数，所以我的分享也只供大家参考，希望大家投稿顺利。

61 0

[GetPortalCommentsPageByObjectIdResponse(id=2127748, encodeId=21ef212e74854, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：2022年7月29日投稿迟迟不外审，过了十月一国庆催了一下稿，外国人不过国庆哈，哈哈哈应该早点催稿 10月28日要求大修 11月17日返稿回去 12月11日接收了 12月20日Proof 12月22日available online 2023年4月正式见刊算是第一篇Sci，感觉还是很顺利的，审稿人的意见很中肯，确实提高了我的稿件质量，投稿体验还不错，如果卡住长时间不动可以发邮件催一下。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230422/fe9c91a3b5ed42adab1bad7bf9101bc7/db18785a63534e8ebf4f6b570394626e.jpg, createdBy=cc6e5681610, createdName=Leonliuy, createdTime=Sat Apr 22 22:29:11 CST 2023, time=2023-04-22, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=1233973, encodeId=9b7012339e316, content=审稿速度:2.0 经验分享：2022.6.2 New submission 2022.6.25 major revisions 2022.7.21 accept 比想象中快，不过这个是投到别的杂志再转投到Neurological Sciences的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=193d5506076, createdName=ms8000001755363788, createdTime=Fri Jul 22 09:33:15 CST 2022, time=2022-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2155735, encodeId=77092155e353b, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：外审回来，审稿人意见都很友好，但是被拒稿了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=32a18153103, createdName=ms9000001040526724, createdTime=Sat Sep 02 10:20:39 CST 2023, time=2023-09-02, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2154020, encodeId=d0ae215402035, content=审稿速度:6.0 | 投稿命中率:25.0 经验分享：无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0c1f3113130, createdName=weina_198062, createdTime=Tue Aug 22 10:32:17 CST 2023, time=2023-08-22, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2110224, encodeId=edb1211022464, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：血管介入方向； 2022-12-15左右投稿； 2023-1-10 小修 2023-1-12 接受 效率可；不过是转投的，至少值得转投吧！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/01/16/e92e0d4a11f64c95514f68e46da6590a.jpg, createdBy=51fb2303021, createdName=errormore, createdTime=Sat Jan 14 20:20:26 CST 2023, time=2023-01-14, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2106655, encodeId=2f012106655f9, content=请问有人知道论文已经Online ahead of print，但是版面费还没交，一般什么时候交版面费啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72f95640939, createdName=ms8000002097345763, createdTime=Mon Dec 19 12:57:14 CST 2022, time=2022-12-19, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2099702, encodeId=df742099e0282, content=审稿速度:2.0 | 投稿命中率:95.0 偏重的研究方向：自身免疫性脑炎;副肿瘤 经验分享：希望审稿周期短一点的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfc76416537, createdName=ms6000000132811253, createdTime=Thu Nov 10 17:49:07 CST 2022, time=2022-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1237916, encodeId=e3d5123e9161a, content=几个第一几个通讯, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dde62288731, createdName=121dfe5cm15暂无昵称, createdTime=Wed Aug 10 20:41:51 CST 2022, time=2022-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226684, encodeId=6e551226684eb, content=投稿命中率:50.0 经验分享：非常慢，甚至应该较很坑的杂志，分享一下自己的投稿撤稿历程：2021.9.25New submission；2021.10.9Editor Assigned；2021.11.4Under Review；2022.1.10Reviewers Invited；2022.1.13Under Review；2022.1.19Reviewers Invited；2022.1.22Under Review；2022.1.29Reviews completed；2022.1.31Editors decision；2022.2.3Major revision；2022.2.9Revision submitted；2022.2.11Editor Assigned；2022.2.15Reviewers Invited；2022.2.19 Under review；2022.2.27Reviewers Invited；2022.3.6Under review；2022.3.10Reviews completed；2022.3.24Reviewers Invited；2022.4.23Reviewers Invited；2022.4.23Under review；2022.5.7withdraw lettter；仍然under review；2022.5.22Reviewers Invited；2022.6.4撤稿成功。总共历时8个月，最终无奈撤稿，期间给编辑发邮件永远收不到回复。当然也能见到少数文章很快被接收，毕竟是少数，所以我的分享也只供大家参考，希望大家投稿顺利。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=450e5455452, createdName=ms4000001879393651, createdTime=Wed Jun 15 22:27:17 CST 2022, time=2022-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=892577, encodeId=b6978925e7ec, content=44天都没有送审，申请撤回了，大家别投了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=158, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ae035128370, createdName=1464e744m37暂无昵称, createdTime=Sat Oct 17 01:02:35 CST 2020, time=2020-10-17, status=1, ipAttribution=)]

2020-10-17 1464e744m37暂无昵称

44天都没有送审，申请撤回了，大家别投了

158 2

展开2条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务